You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nodal marginal zone lymphoma

Showing 1 - 25 of 6,798
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Molecular Taxonomy of Nodal Marginal Zone Lymphoma

Not yet recruiting
  • Nodal Marginal Zone Lymphoma
    • Paris, France
    • +2 more
    Jan 17, 2023

    Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

    Withdrawn
    • Recurrent Follicular Lymphoma
    • +8 more
    • (no location specified)
    Jun 2, 2022

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

    Suspended
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +23 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Feb 23, 2022

    Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

    Not yet recruiting
    • Mature B-Cell Neoplasm
    • +25 more
    • (no location specified)
    Sep 14, 2022

    Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma Trial in Worldwide (Ibrutinib, Rituximab)

    Recruiting
    • Marginal Zone Lymphoma
    • +2 more
    • Yvoir, Belgium
    • +36 more
    Nov 4, 2022

    Mantle Cell Lymphoma, Follicular Lymphoma, Splenic Marginal Zone Lymphoma Trial in Chapel Hill (CAR.k.28, Fludarabine,

    Recruiting
    • Mantle Cell Lymphoma
    • +5 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Nov 19, 2021

    Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of

    Active, not recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +22 more
    • Scottsdale, Arizona
    • +1 more
    Aug 10, 2021

    MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

    Completed
    • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
    • +8 more
    • PI3K inhibitor BKM120
    • +3 more
    • Atlanta, Georgia
    • +1 more
    Jun 27, 2022

    Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

    Active, not recruiting
    • Adult Grade III Lymphomatoid Granulomatosis
    • +23 more
    • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
    • +2 more
    • Duarte, California
      City of Hope Medical Center
    Jan 4, 2023

    MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

    Active, not recruiting
    • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
    • +9 more
    • BTK inhibitor PCI-32765
    • +5 more
    • Columbus, Ohio
      Ohio State University Medical Center
    Jun 27, 2022

    Non-Hodgkin's Lymphoma, Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Ann Arbor

    Recruiting
    • Non-Hodgkin's Lymphoma
    • +18 more
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Mar 11, 2021

    Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

    Completed
    Has Results
    • Adult Nasal Type Extranodal NK/T-cell Lymphoma
    • +20 more
    • Scottsdale, Arizona
    • +1 more
    May 6, 2022

    Marginal Zone Lymphoma Trial ([68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose)

    Not yet recruiting
    • Marginal Zone Lymphoma
    • (no location specified)
    Nov 6, 2023

    OR Regimen Refractory Marginal Zone Lymphoma Trial (obrutinib, rituximab)

    Not yet recruiting
    • OR Regimen Refractory Marginal Zone Lymphoma
    • obrutinib, rituximab
    • (no location specified)
    Nov 12, 2023

    Marginal Zone Lymphoma Trial in Tianjin (Obinutuzumab, lenalidomide)

    Recruiting
    • Marginal Zone Lymphoma
    • Obinutuzumab, lenalidomide
    • Tianjin, Tian, China
      Institute of Hematology & Blood Diseases Hospital
    Apr 27, 2023

    Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma Trial in Boston (Obinutuzumab, Glofitamab)

    Not yet recruiting
    • Follicular Lymphoma
    • +2 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    Mar 13, 2023

    Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell

    Active, not recruiting
    • Adult Grade III Lymphomatoid Granulomatosis
    • +71 more
    • Chicago, Illinois
    • +5 more
    Oct 8, 2021

    Marginal Zone Lymphoma Trial (Mosunetuzumab + Lenalidomide, - Rituximab + Lenalidomide (28-days cycles, - Rituximab +

    Not yet recruiting
    • Marginal Zone Lymphoma
    • Mosunetuzumab + Lenalidomide
    • +3 more
    • (no location specified)
    Aug 16, 2023

    Marginal Zone Lymphoma Trial in Germany (Obinutuzumab)

    Active, not recruiting
    • Marginal Zone Lymphoma
    • Bochum, Germany
    • +15 more
    Nov 4, 2022

    Relapsed/Refractory Marginal Zone Lymphoma Trial in China (Orelabrutinib, Lenalidomide, Rituximab)

    Not yet recruiting
    • Relapsed/Refractory Marginal Zone Lymphoma
    • Guangzhou, Guangdong, China
    • +10 more
    Oct 8, 2023

    Lymphoma Trial (Ultra Low Dose 4 Gy Radiation)

    Not yet recruiting
    • Lymphoma
    • Ultra Low Dose 4 Gy Radiation
    • (no location specified)
    Jun 30, 2023

    Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

    Active, not recruiting
    • Indolent Non-hodgkin Lymphoma
    • Shanghai, China
      Ruijin hospital, school of medicine, Shanghai jiao tong universi
    Oct 3, 2022

    Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma (MZL) Trial in Chiang Mai (Odronextamab, Lenalidomide,

    Recruiting
    • Relapsed/Refractory Follicular Lymphoma
    • Marginal Zone Lymphoma (MZL)
    • Chiang Mai, Thailand
      Chiang Mai University
    Nov 20, 2023

    Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma

    Terminated
    Has Results
    • Adult Grade III Lymphomatoid Granulomatosis
    • +116 more
    • brentuximab vedotin
    • +2 more
    • Chicago, Illinois
    • +2 more
    Aug 30, 2021

    Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

    Recruiting
    • Relapsed/Refractory Follicular Lymphoma
    • Marginal Zone Lymphoma
    • Westbury, New York
      Clinical Research Alliance, Inc.
    Nov 14, 2022